GSK opens S$130m facilities in Jurong
New plant and expanded building will step up pharmaceutical firm's output of active ingredients in its HIV medication
Add BT as a preferred source
Singapore
PHARMACEUTICAL giant GlaxoSmithKline (GSK) unveiled a new, fully automated continuous manufacturing facility and an expanded production building at its Jurong site on Friday, worth a total of S$130 million.
The site upgrades will accelerate GSK's global supply chain and, in particular, its production of active pharmaceutical ingredients (APIs) such as Dolutegravir and Lamivudine, key assets in GSK's HIV medication.
TRENDING NOW
DBS, OCBC and UOB shares hit all-time highs as sentiment improves
Targeted credit relief: Vietnam steers funding to Vingroup, Sun Group, Masterise megaprojects
E-commerce job cuts signal S-E Asia’s shift from scaling to deeper user engagement
Employers want AI-fluent employees. Hiring them is the challenge
